Leidos is the largest pure-play U.S. government IT/defense services contractor, but the June 2026 decision by the Defense Health Agency to strip Leidos of its systems-integrator role on MHS GENESIS — the flagship military electronic-health-record program — is a genuine moat event, not a headline scare: the customer is disaggregating the program and self-integrating, contracting directly with Oracle Health and the other OEMs through July 2027. That proves the central 'near-unbreachable switching cost' claim was overstated on the integration layer, and it comes amid a sector-wide GSA/DOGE push to target large integrators and shift to outcomes-based contracting. Offsetting this, Q1 FY2026 was a beat-and-raise (adj EPS $3.13, revenue $4.40B, FY26 guide lifted to $18.0-18.4B) and the defense franchise is booking heavily ($2.7B Army 'Dark Eagle' hypersonics production, $10B State Dept 'Evolve' IT ceiling, $869M Army MACRO), while the ENTRUST energy acquisition diversifies away from the 87% government concentration. At ~8.9x forward non-GAAP EPS and 1.5% yield the stock prices in real impairment, but the moat de-rate caps the multiple re-rating the prior bull case relied on — this is now a deep-value HOLD, not a compounder BUY.